Journal article
Mutant mice with calcium-sensing receptor (CaSR) activation have hyperglycemia, that is rectified by calcilytic therapy
- Abstract:
- The calcium-sensing receptor (CaSR) is a family C G-protein-coupled receptor (GPCR) that plays a pivotal role in extracellular calcium homeostasis. The CaSR is also highly expressed in pancreatic islet α- and β-cells that secrete glucagon and insulin, respectively. To determine whether the CaSR may influence systemic glucose homeostasis, we characterized a mouse model with a germline gain-of-function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf). Heterozygous- (CasrNuf/+) and homozygous-affected (CasrNuf/Nuf) mice were shown to have hypocalcemia in association with impaired glucose tolerance and insulin secretion. Oral administration of a CaSR antagonist compound, known as a calcilytic, rectified the glucose intolerance and hypoinsulinemia of CasrNuf/+ mice, and ameliorated glucose intolerance in CasrNuf/Nuf mice. Ex vivo studies showed CasrNuf/+ and CasrNuf/Nuf mice to have reduced pancreatic islet mass and β-cell proliferation. Electrophysiological analysis of isolated CasrNuf/Nuf islets showed CaSR activation to increase the basal electrical activity of β-cells independently of effects on the activity of the ATP-sensitive K+ (KATP) channel. CasrNuf/Nuf mice also had impaired glucose-mediated suppression of glucagon secretion, which was associated with increased numbers of α-cells and a higher α-cell proliferation rate. Moreover, CasrNuf/Nuf islet electrophysiology demonstrated an impairment of α-cell membrane depolarization in association with attenuated α-cell basal KATP channel activity. These studies indicate that the CaSR activation impairs glucose tolerance by a combination of α- and β-cell defects and also influences pancreatic islet mass. Moreover, our findings highlight a potential application of targeted CaSR compounds for modulating glucose metabolism.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.7MB, Terms of use)
-
- Publisher copy:
- 10.1210/en.2017-00111
Authors
+ GlaxoSmithKline
More from this funder
- Funding agency for:
- Thakker, R
- Hannan, F
- Grant:
- FP7-264663
- G1000467
+ Marie Curie
More from this funder
- Funding agency for:
- Kallay, E
- Thakker, R
- Grant:
- FP7-264663
- FP7-264663
+ National Institute for Health Research
More from this funder
- Funding agency for:
- Nesbit, M
- Thakker, R
- Grant:
- G1000467
- FP7-264663
+ Medical Research Council
More from this funder
- Funding agency for:
- Nesbit, M
- Stewart, M
- Wells, S
- Cox, R
- Hannan, F
- Hugill, A
- Bentley, L
- Hough, T
- Thakker, R
- Joynson, E
- Grant:
- G1000467
- MC_U142661184
- MC_U142661184
- MC_U142661184
- G1000467
- MC_U142661184
- MC_U142661184
- MC_U142661184
- FP7-264663
- MC_U142661184
- Publisher:
- Oxford University Press
- Journal:
- Endocrinology More from this journal
- Volume:
- 158
- Issue:
- 8
- Pages:
- 2486-2502
- Publication date:
- 2017-06-02
- Acceptance date:
- 2017-05-30
- DOI:
- EISSN:
-
1945-7170
- ISSN:
-
0013-7227
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:698624
- UUID:
-
uuid:8041bf03-4ac7-4faf-85dc-f9866b894bb5
- Local pid:
-
pubs:698624
- Source identifiers:
-
698624
- Deposit date:
-
2017-06-20
Terms of use
- Copyright holder:
- Babinsky et al
- Copyright date:
- 2017
- Notes:
- This article has been published under the terms of the Creative Commons Attribution License (CC BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record